PE20121359A1 - PHARMACEUTICAL COMPOSITION INCLUDING OLIGOPEPTIDES - Google Patents

PHARMACEUTICAL COMPOSITION INCLUDING OLIGOPEPTIDES

Info

Publication number
PE20121359A1
PE20121359A1 PE2012000796A PE2012000796A PE20121359A1 PE 20121359 A1 PE20121359 A1 PE 20121359A1 PE 2012000796 A PE2012000796 A PE 2012000796A PE 2012000796 A PE2012000796 A PE 2012000796A PE 20121359 A1 PE20121359 A1 PE 20121359A1
Authority
PE
Peru
Prior art keywords
pharmaceutical composition
gly
asp
arg
composition including
Prior art date
Application number
PE2012000796A
Other languages
Spanish (es)
Inventor
Marcus Eber
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44145957&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121359(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PE20121359A1 publication Critical patent/PE20121359A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Abstract

REFERIDA A UNA COMPOSICION QUE COMPRENDE: a) 12% A 90% DE UN OLIGOPEPTIDO TAL COMO CICLO-(Arg-Gly-Asp-DPhe-NMeVal), CICLO-(Arg-Gly-Asp-DPhe-vAL), Arg-Gly-Asp, ENTRE OTROS, b) 0,01% A 60% DE UNO O VARIOS COMPUESTOS LIPOFILICOS Y/O ANFIFILICOS, Y OPCIONALMENTE, c) 0% A 89% DE AGUA, DONDE LOS COMPUESTOS LIPOFILICOS Y/O ANFIFILICOS COMPRENDEN UN RESTO GLICEROL, UNO O VARIOS RESTOS DE ACIDOS GRASOS Y/O UNO O VARIOS RESTOS DE ALCOHOLES GRASOS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICAREFERRED TO A COMPOSITION THAT INCLUDES: a) 12% TO 90% OF AN OLIGOPEPTIDE SUCH AS CYCLE- (Arg-Gly-Asp-DPhe-NMeVal), CYCLE- (Arg-Gly-Asp-DPhe-vAL), Arg-Gly -Asp, AMONG OTHERS, b) 0.01% TO 60% OF ONE OR SEVERAL LIPOPHILIC AND / OR AMPHIFILIC COMPOUNDS, AND OPTIONALLY, c) 0% TO 89% OF WATER, WHERE THE LIPOPHILIC AND / OR AMPHYPHILIC COMPOUNDS INCLUDE A REST GLYCEROL, ONE OR SEVERAL REMAINS OF FATTY ACIDS AND / OR ONE OR SEVERAL REMAINS OF FATTY ALCOHOLS. IT IS ALSO REFERRED TO A PHARMACEUTICAL COMPOSITION

PE2012000796A 2009-12-10 2010-12-06 PHARMACEUTICAL COMPOSITION INCLUDING OLIGOPEPTIDES PE20121359A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28531309P 2009-12-10 2009-12-10
US41662810P 2010-11-23 2010-11-23

Publications (1)

Publication Number Publication Date
PE20121359A1 true PE20121359A1 (en) 2012-10-15

Family

ID=44145957

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000796A PE20121359A1 (en) 2009-12-10 2010-12-06 PHARMACEUTICAL COMPOSITION INCLUDING OLIGOPEPTIDES

Country Status (19)

Country Link
US (1) US9433577B2 (en)
EP (1) EP2509583B1 (en)
JP (1) JP5946770B2 (en)
KR (1) KR20120104316A (en)
CN (1) CN102652015B (en)
AU (1) AU2010330364B2 (en)
BR (1) BR112012012862A2 (en)
CA (1) CA2783732A1 (en)
CL (1) CL2012001310A1 (en)
EA (1) EA022700B1 (en)
EC (1) ECSP12012031A (en)
ES (1) ES2742263T3 (en)
IL (1) IL220097A (en)
MX (1) MX2012006450A (en)
NZ (1) NZ601109A (en)
PE (1) PE20121359A1 (en)
SG (1) SG181487A1 (en)
WO (1) WO2011069629A2 (en)
ZA (1) ZA201205103B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011012231A (en) * 2009-05-20 2011-12-08 Merck Patent Gmbh Novel solid materials of {[2s, 5r,8s,11s)-5-benzyl-11-(3-guanidin o-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13- pentaaza-cyclopentadec-2-yl]-acetic acid} and methods for obtaining them.
CN105648056A (en) 2010-05-14 2016-06-08 综合医院公司 Composite and method for detecting tumor specific novel antigen
EP2717854B1 (en) * 2011-06-09 2019-01-16 Merck Patent GmbH Treatment of cancers and metastases with suspensions of cilengitide in carrier
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CA2934073A1 (en) 2013-12-20 2015-06-25 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
US10835585B2 (en) 2015-05-20 2020-11-17 The Broad Institute, Inc. Shared neoantigens
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
TWI783890B (en) 2017-08-24 2022-11-11 丹麥商諾佛 儂迪克股份有限公司 Glp-1 compositions and uses thereof
WO2019126186A1 (en) 2017-12-18 2019-06-27 Neon Therapeutics, Inc. Neoantigens and uses thereof
AU2021208601A1 (en) 2020-02-18 2022-07-28 Novo Nordisk A/S Glp-1 compositions and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06507172A (en) * 1991-04-19 1994-08-11 アフィニティー　バイオテック，インコーポレイテッド Convertible microemulsion formulation
NZ243721A (en) * 1991-07-26 1994-11-25 Smithkline Beecham Corp Self-emulsifying microemulsion comprising water soluble drug, high hlb surfactant and a lipophilic phase containing fatty acid triglyceride and a low hlb surfactant
DE19534177A1 (en) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclic adhesion inhibitors
AU719085B2 (en) * 1996-08-22 2000-05-04 Rtp Pharma Corporation Processes of preparing or stabilising microparticles
DE19842415A1 (en) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmaceutical preparation for treating e.g. tumors, thrombosis or inflammation, contains cyclic pentapeptide integrin inhibitor and chemotherapeutic agent and/or angiogenesis inhibitor
UA71608C2 (en) 1999-03-11 2004-12-15 Merck Patent Gmbh A method for producing the cyclic pentapeptide
US7060672B2 (en) * 2001-10-19 2006-06-13 Isotechnika, Inc. Cyclosporin analog formulations
US6656460B2 (en) * 2001-11-01 2003-12-02 Yissum Research Development Method and composition for dry eye treatment
DE10228049A1 (en) * 2002-06-24 2004-01-15 Merck Patent Gmbh Liquid preparation containing oligopeptides
KR20060012628A (en) 2003-05-19 2006-02-08 백스터 인터내셔널 인코포레이티드 Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers
US7749485B2 (en) * 2004-06-03 2010-07-06 Bracco Research S.A. Liposomal assembly for therapeutic and/or diagnostic use
US20100190716A1 (en) * 2007-09-11 2010-07-29 Dorian Bevec Use of a platelet fibrinogen receptor hexapeptide antagonist and alpha-endorphin as therapeutic agents
WO2009124754A1 (en) * 2008-04-08 2009-10-15 Merck Patent Gmbh Compositions containing cyclic peptides and methods of use
MX2011012231A (en) * 2009-05-20 2011-12-08 Merck Patent Gmbh Novel solid materials of {[2s, 5r,8s,11s)-5-benzyl-11-(3-guanidin o-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13- pentaaza-cyclopentadec-2-yl]-acetic acid} and methods for obtaining them.

Also Published As

Publication number Publication date
AU2010330364A1 (en) 2012-07-26
CN102652015A (en) 2012-08-29
ECSP12012031A (en) 2012-08-31
EA022700B1 (en) 2016-02-29
US20120288539A1 (en) 2012-11-15
JP2013513556A (en) 2013-04-22
CN102652015B (en) 2016-08-03
CA2783732A1 (en) 2011-06-16
EA201200850A1 (en) 2013-01-30
ES2742263T3 (en) 2020-02-13
JP5946770B2 (en) 2016-07-06
NZ601109A (en) 2014-06-27
EP2509583B1 (en) 2019-05-15
KR20120104316A (en) 2012-09-20
AU2010330364B2 (en) 2016-05-19
BR112012012862A2 (en) 2016-08-16
WO2011069629A2 (en) 2011-06-16
ZA201205103B (en) 2013-03-27
SG181487A1 (en) 2012-07-30
US9433577B2 (en) 2016-09-06
EP2509583A2 (en) 2012-10-17
MX2012006450A (en) 2012-06-28
IL220097A (en) 2017-03-30
CL2012001310A1 (en) 2012-10-12
WO2011069629A3 (en) 2012-03-15

Similar Documents

Publication Publication Date Title
PE20121359A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING OLIGOPEPTIDES
CY1119784T1 (en) ACUTYLIED SALICYLIC ACID COMPOUNDS AND THEIR USES
CY1120888T1 (en) TRANSPARENT PHARMACEUTICAL COMPOSITIONS INCLUDING ACTIVE AGENTS
ES2580635T3 (en) Cosmetic composition comprising a structuring agent, an absorbent agent and a surfactant for application to keratin materials
UY34112A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING A NEUROLEPTIC AGENT AND A SGLT2 INHIBITOR AND USES OF THE SAME
ITVA20110027A1 (en) COMPOSITIONS FOR CARE OF THE PERSON
CL2013000304A1 (en) Compounds derived from prostaglandin e2 inhibitor 2-arylamino-benzimidazoles (mpges-1); pharmaceutical composition that includes them; intermediary compounds; use in the treatment of inflammatory diseases and / or associated conditions, in particular pain.
CO7160059A2 (en) Liquid formulation
ECSP10010433A (en) COMPOSITION UNDERSTANDING ANTIBODY FIXED TO DOMAIN II OF HER2, AND ITS VARIOUS ACIDS
AR082051A1 (en) ANTIMICROBIAL COMPOSITION FOR REDUCED ORAL RINSE IN ALCOHOL
CL2012000573A1 (en) Compounds derived from biphenyl-pyrrolidinyl-imidazole; pharmaceutical composition comprising them; its use in the treatment of an hcv viral infection.
CO6491099A2 (en) SYSTEMS FOR ORAL CARE
ES2721148T3 (en) Pharmaceutical compositions of paclitaxel, paclitaxel analogues or paclitaxel conjugates and related methods of preparation and use
AR089007A1 (en) ADDITIVE COMPOSITION FOR WELL TREATMENT FLUIDS
CO6210786A2 (en) IMPLEMENTATION OF ORAL CARE WHICH HAS AN ORAL CARE AGENT
CL2012002742A1 (en) Stable aqueous alkali metal silicate composition comprising an osmolyte; use of said composition to protect crops or to prepare pharmaceutical or cosmetic composition or a food or food supplement.
CL2008003907A1 (en) Cleaning compositions comprising alkyl polyglucoside, alcohol of 2 to 4 carbon atoms, glycerol, and optional components, such as water soluble organic acids, fragrances, builders;
CO6531452A2 (en) SUBSTITUTED PIPERIDINS THAT INCREASE THE ACTIVITY OF P53 AND ITS USES
ECSP088214A (en) BAZEDOXIFEN ACETATE FORMULATIONS THAT HAVE A REDUCED POLYMORPHIC CONVERSION
ES2484721T3 (en) Fluidizing mixture for hydraulic composition
CL2013002234A1 (en) Use of a pharmaceutical composition comprising at least one prostacyclin or an analogue thereof selected from treprostinil, ilorpost, cicaprost or beraprost, and at least one phosphodiesterase 4 (pde4) inhibitor, because it serves in the prevention or treatment of cystic fibrosis .
AR078142A1 (en) BICYCLE HYDEROARILIC PDE4 INHIBITOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THE USE OF THEM FOR THE PREPARATION OF MEDICINES.
AR094015A1 (en) METHODS FOR WHITENING TEETH
NO20071485L (en) Chemical substances.
MX2016001129A (en) Transparent sunscreen compositions and use thereof.

Legal Events

Date Code Title Description
FD Application declared void or lapsed